Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsPRNewsWire • 03/27/24
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentPRNewsWire • 03/27/24
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZPRNewsWire • 03/19/24
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticPRNewsWire • 02/26/24
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024PRNewsWire • 02/13/24
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsPRNewsWire • 01/18/24
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesPRNewsWire • 12/05/23
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITPRNewsWire • 11/14/23
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023PRNewsWire • 11/10/23
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryPRNewsWire • 10/05/23
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsPRNewsWire • 10/02/23
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesPRNewsWire • 09/15/23
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesPRNewsWire • 09/13/23
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaPRNewsWire • 09/13/23
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsPRNewsWire • 09/11/23
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaPRNewsWire • 09/06/23
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's DiseasePRNewsWire • 08/09/23
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical TrialPRNewsWire • 07/25/23
Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical SitePRNewsWire • 06/14/23
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's DiseasePRNewsWire • 06/06/23